On the public citation graph
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
0 signed · 68 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/1097-0142(19930701)72:1<37::aid-cncr2820720109>3.0.co;2-popenalex-snapshot
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer
inferredcites →https://doi.org/10.1002/14651858.cd004064.pub3openalex-snapshot
Chemotherapy for advanced gastric cancer
inferredcites →https://doi.org/10.1002/14651858.cd004064.pub4openalex-snapshot
Chemotherapy for advanced gastric cancer
inferredcites →https://doi.org/10.1002/ijc.26080openalex-snapshot
Trends of stomach cancer mortality in Eastern Asia in 1950–2004: comparative study of Japan, Hong Kong and Singapore using age, period and cohort analysis
inferredcites →https://doi.org/10.1002/sim.1653openalex-snapshot
On the estimation of the binomial probability in multistage clinical trials
inferredcites →https://doi.org/10.1007/978-3-642-67368-9_53openalex-snapshot
Chemotherapy in Advanced Gastric Cancer
inferredcites →https://doi.org/10.1007/s00280-007-0515-7openalex-snapshot
Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
inferredcites →https://doi.org/10.1007/s00280-012-1982-zopenalex-snapshot
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
inferredcites →https://doi.org/10.1007/s10637-009-9363-0openalex-snapshot
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
inferredcites →https://doi.org/10.1007/s10637-013-0032-yopenalex-snapshot
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer
inferredcites →https://doi.org/10.1007/s10637-013-9938-7openalex-snapshot
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer
inferredcites →https://doi.org/10.1016/0360-3016(90)90344-jopenalex-snapshot
Patterns of failure following curative resection of gastric carcinoma
inferredcites →https://doi.org/10.1016/s0140-6736(10)61121-xopenalex-snapshot
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(12)60651-5openalex-snapshot
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
inferredcites →https://doi.org/10.1023/a:1008243606668openalex-snapshot
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer
inferredcites →https://doi.org/10.1038/bjc.2013.470openalex-snapshot
Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
inferredcites →https://doi.org/10.1038/sj.bjc.6601896openalex-snapshot
Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view
inferredcites →https://doi.org/10.1038/sj.bjc.6605366openalex-snapshot
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
inferredcites →https://doi.org/10.1038/sj.bjc.6690350openalex-snapshot
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial
inferredcites →https://doi.org/10.1046/j.1365-2168.2000.01360.xopenalex-snapshot
Recurrence following curative resection for gastric carcinoma
inferredcites →https://doi.org/10.1056/nejmoa021491openalex-snapshot
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
inferredcites →https://doi.org/10.1056/nejmoa032691openalex-snapshot
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
inferredcites →https://doi.org/10.1056/nejmoa060655openalex-snapshot
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa065044openalex-snapshot
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1056/nejmoa073149openalex-snapshot
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
inferredcites →https://doi.org/10.1056/nejmoa1303989openalex-snapshot
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1080/00401706.1983.10487819openalex-snapshot
Confidence Intervals for a Binomial Parameter Following a Multistage Test With Application to MIL-STD 105D and Medical Trials
inferredcites →https://doi.org/10.1080/10543400600825645openalex-snapshot
p-Value Calculation for Multistage Phase II Cancer Clinical Trials
inferredcites →https://doi.org/10.1093/annonc/mdm496openalex-snapshot
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
inferredcites →https://doi.org/10.1093/annonc/mdp011openalex-snapshot
Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
inferredcites →https://doi.org/10.1093/annonc/mdp466openalex-snapshot
Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib
inferredcites →https://doi.org/10.1097/jto.0000000000000005openalex-snapshot
An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1126/science.1104819openalex-snapshot
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-2740openalex-snapshot
Phase I Trial of Pazopanib in Patients with Advanced Cancer
inferredcites →https://doi.org/10.1158/1535-7163.mct-11-0997openalex-snapshot
Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors
inferredcites →https://doi.org/10.1200/jco.2006.06.8429openalex-snapshot
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
inferredcites →https://doi.org/10.1200/jco.2006.07.3049openalex-snapshot
Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria
inferredcites →https://doi.org/10.1200/jco.2006.09.6305openalex-snapshot
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
inferredcites →https://doi.org/10.1200/jco.2009.27.7988openalex-snapshot
Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203
inferredcites →https://doi.org/10.1200/jco.2010.32.0770openalex-snapshot
Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
inferredcites →https://doi.org/10.1200/jco.2011.36.2236openalex-snapshot
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
inferredcites →https://doi.org/10.1200/jco.2013.50.8267openalex-snapshot
Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
inferredcites →https://doi.org/10.1634/theoncologist.2009-0274openalex-snapshot
(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
inferredcites →https://doi.org/10.1634/theoncologist.2013-0391openalex-snapshot
10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study
inferredcites →https://doi.org/10.4143/crt.2012.44.1.11openalex-snapshot
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2009
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.5016626openalex-extracted
Vasculopathy in the Correa's Cascade of Gastric Cancer: Pathological Features and Phytotherapy Strategy
inferred← citeshttps://doi.org/10.1002/ccr3.4986openalex-snapshot
Response to pazopanib‐based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma
inferred← citeshttps://doi.org/10.1002/ijc.33864openalex-snapshot
Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO ‐0510
inferred← citeshttps://doi.org/10.1007/978-3-030-28891-4_10openalex-snapshot
Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Peritoneal Metastasis of Gastric Cancer
inferred← citeshttps://doi.org/10.1007/s12029-018-0130-3openalex-snapshot
Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.4c00246openalex-snapshot
Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects
inferred← citeshttps://doi.org/10.1038/s41419-023-05568-8openalex-snapshot
Hippo pathway dysregulation in gastric cancer: from Helicobacter pylori infection to tumor promotion and progression
inferred← citeshttps://doi.org/10.1080/13543784.2017.1361926openalex-snapshot
Angiogenesis inhibitors in early development for gastric cancer
inferred← citeshttps://doi.org/10.1111/ajco.13174openalex-snapshot
Anti‐angiogenic therapies for gastric cancer
inferred← citeshttps://doi.org/10.1186/s40164-019-0149-6openalex-snapshot
Targeted and novel therapy in advanced gastric cancer
inferred← citeshttps://doi.org/10.21037/atm-20-3510openalex-snapshot
Does tumor profile in gastric and gastroesophageal (GE) junction cancer justify off-label use of targeted therapy?—a narrative review
inferred← citeshttps://doi.org/10.3389/fonc.2022.993573openalex-snapshot
Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma
inferred← citeshttps://doi.org/10.3389/fonc.2023.1148131openalex-snapshot
Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer
inferred← citeshttps://doi.org/10.3389/fonc.2025.1654300openalex-snapshot
Clinical advances and challenges of anti-angiogenic targeted therapy in gastric cancer
inferred← citeshttps://doi.org/10.3390/cancers13235915openalex-snapshot
Early TP53 Alterations Shape Gastric and Esophageal Cancer Development
inferred← citeshttps://doi.org/10.3390/cancers14225615openalex-snapshot
Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer
inferred← citeshttps://doi.org/10.3390/jcm12093226openalex-snapshot
The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review
inferred← citeshttps://doi.org/10.3748/wjg.v22.i19.4638openalex-snapshot
Recent updates of precision therapy for gastric cancer: Towards optimal tailored management
inferred← citeshttps://doi.org/10.3892/ol.2019.10820openalex-snapshot
Prognostic value and association of Lauren classification with VEGF and VEGFR‑2 expression in gastric cancer
inferred← citeshttps://doi.org/10.3904/kjm.2018.93.1.14openalex-snapshot
Novel Therapeutics for Recurrent or Metastatic Gastric Cancer
inferred← citeshttps://doi.org/10.4143/crt.2016.176openalex-snapshot
Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.